Please assess the completion status of the following clinical trial:

Trial Title: BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male/female aged 19 to 55 with body mass index(BMI) between 18.5 and 30kg/m2~* Acceptable medical history, physical examination, laboratory tests and EKG, during screening~* Subjects who has signed a written informed consent voluntarily~Exclusion Criteria:~* History of clinically significant medical history or current disease~* Hypotension (SBP ≤ 90 mmHg or DBP ≤ 60 mmHg) or hypertension (SBP~  ≥ 140 mmHg or DBP ≥ 90 mmHg).~* AST(SGOT) or/and ALT(SGPT) \> 1.5 times of normal upper limit~* Total bilirubin \> 2.0 mg/dl~* Volunteers considered not eligible for the clinical trial by the investigator~* Administration of other investigational products within 6 month prior to the first dosing.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Group1 (Type: EXPERIMENTAL): 17 subjects, Cross-over, Single dose of comparator on day1, YHP1807 on day8
- Group2 (Type: ACTIVE_COMPARATOR): 17 subjects, Cross-over, Single dose of YHP1807 on day1, comparator on day8

Based on this trial design, predict the completion outcome and termination type (if applicable).